Herpesvirus replication defective mutants
US7223411B1 · kind B1 · utility
6Cited by
11References
38Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 21, 1994 |
| Grant date | May 29, 2007 |
| Priority date | — |
| Expiry date | Jul 21, 2014 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/16661
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A herpesvirus vaccine comprising a mutated herpesvirus suspended in a pharmaceutically acceptable carrier. The mutated herpesvirus is capable of infecting cells of the mammal to be vaccinated, but incapable of completing a replicative cycle, and it is capable of eliciting a protective immune response in that mammal. The mutated herpesvirus is also capable of treating immunomodulatory or immunoregulatory diseases. The mutation occurs in at least one gene encoding a protein essential for replication of the virus, so that the mutation renders the virus replication defective.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.